• EU regulators approve Takeda's Adcetris for sALCL pharmatimes
    May 15, 2020
    European regulators have approved Takeda's Adcetris (brentuximab vedotin) for use in adults with previously untreated systemic anaplastic large cell lymphoma (sALCL) in combination with CHP (cyclophosphamide, doxorubicin, prednisone).
PharmaSources Customer Service